Vitamin K2 compositions for the treatment of drug induced neuropathy

Abstract

The present invention provides the use of vitamin K2 compositions for the treatment of drug-induced neuropathy. More particularly it is related to the use of vitamin K2-7 compositions for the treatment of drug-induced peripheral neuropathy caused by the drugs used for the treatment of multiple myeloma.

We claim: 
     
       1. A method of treating or ameliorating a symptom of cancer drug-induced peripheral neuropathy in a patient suffering from multiple myeloma, the method comprising administering a composition consisting essentially of vitamin K2-7 to the patient, wherein the peripheral neuropathy is caused by the cancer drug used in the treatment of multiple myeloma and the vitamin K2-7 is effective in treating or ameliorating at least one symptom of cancer drug-induced peripheral neuropathy. 
     
     
       2. The method of  claim 1 , wherein the cancer drug used in the treatment of multiple myeloma is selected from the group consisting of a proteasome inhibitor, an immune suppressant, a steroid, a corticosteroid, an immune modulator, a bisphosphonate, a monoclonal antibody, a vinca alkaloid, and combinations thereof. 
     
     
       3. The method of  claim 2 , wherein the proteasome inhibitor is Bortezomib. 
     
     
       4. The method of  claim 2 , wherein the immune suppressant is Cyclophosphamide. 
     
     
       5. The method of  claim 2 , wherein the steroid is Prednisolone. 
     
     
       6. The method of  claim 2 , wherein the corticosteroid is Dexamethasone. 
     
     
       7. The method of  claim 2 , wherein the immune modulator is lenalidomide. 
     
     
       8. The method of  claim 2 , wherein the bisphosphonate is zoledronic acid. 
     
     
       9. The method of  claim 2 , wherein the monoclonal antibody is Rituximab. 
     
     
       10. The method of  claim 2 , wherein the vinca alkaloid is vincristine. 
     
     
       11. The method of  claim 1 , wherein the dose of vitamin K2-7 is in the range of 50 μg/day to 1100 μg/day. 
     
     
       12. The method of  claim 1 , wherein the duration for lowering the symptoms of the drug induced peripheral neuropathy from severe to mild is in the range 2-5 months. 
     
     
       13. A method of preventing the symptoms of cancer drug-induced peripheral neuropathy in a patient suffering from multiple myeloma, the method comprising administering vitamin K2-7 to the patient, wherein the peripheral neuropathy is caused by the cancer drug used in the treatment of multiple myeloma and the vitamin K2-7 is effective in treating or ameliorating at least one symptom of cancer drug-induced peripheral neuropathy.